Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis

NCT02424396 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG: IL2
DRUG: Placebo

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]